MALVERN, Pa. (AP) _ Aclaris Therapeutics Inc. (ACRS) on Monday reported a loss of $22.9 million in its fourth quarter.
On a per-share basis, the Malvern, Pennsylvania-based company said it had a loss of 74 cents. Losses, adjusted for pretax gains, came to 80 cents per share.
The results beat Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 90 cents per share.
The specialty pharmaceutical company posted revenue of $999,000 in the period.
For the year, the company reported that its loss widened to $68.5 million, or $2.44 per share. Revenue was reported as $1.7 million.
Aclaris shares have declined 14 percent since the beginning of the year. The stock has dropped 32 percent in the last 12 months.